𝕋𝕙𝕖 π•Žπ•šπ•₯𝕔𝕙 π•¨π•šπ•₯𝕙 π•₯𝕙𝕖 𝔽𝕝𝕠𝕨𝕖𝕣 𝕋𝕒π•₯π•₯𝕠𝕠𝕀 βšΈπ–€

@prettytiired.bsky.social

Β©1986 she/her β™ΏπŸ³οΈβ€πŸŒˆπŸˆβ€β¬›πŸ¦„πŸ”ž Life's short and hard, like a body building elf

⚠️ Phishing Warning A fake website (velvat22) is attempting to steal Velvet22 accounts. βœ… Only log in at: velvet22.com πŸ”’ Enable 2FA and never enter your password on any other website. Always check the URL before signing in.

In our attempts to curb the burgeoning symptoms of E.L.D.S. (evil little dog syndrome) in Hector, we have now introduced "potato time" where I pick him up, hold him in midair and tell him what an adorable little potato he is until he calms his tiny chihuahua tits. 45% success rate so far.

Once rapidly fatal diseases without approved therapeutic options, systemic amyloidoses are now highly treatable. A new Review summarises treatment advancements and future directions in systemic light chain and transthyretin amyloidosis: spkl.io/633277KhbB

Human body with annotations showing potential organs or systems involved by AL or ATTR amyloidosis. Red colour indicates organs or systems mostly or uniquely involved by AL amyloidosis. Green colour indicates those mostly or uniquely involved by ATTRwt amyloidosis. Blue colour indicates sites of clinical presentation common to both. AL=light chain amyloidosis. ATTR=transthyretin amyloidosis. ATTRv=transthyretin amyloidosis variant. ATTRwt=transthyretin amyloidosis wild-type. *Also common in ATTRv. Copyright: 2026 Elsevier Ltd. All rights are reserved.

Good morning yall, This is a perfect example of "don't like? don't look". A thing isn't *ruined* just because you don't like the kink or fetish. If you don't like it, don't look and keep scrolling and/or block/mute. πŸ˜‰. Same goes for any kink on NSFW... Cheers.

Post nicht verfΓΌgbar.

I forgot it was disability pride month, with everything going on I feel like no support and love was given. I hope others atleast spread awareness and mental health gets taken even more seriously in the future, wish it was in the now.

Amyloidosis care has changed dramatically in the last decade. New therapies, better diagnosis, and multidisciplinary collaboration have improved outcomesβ€”but access remains unequal. What can other rare diseases learn from this progress? Our Editorial: tinyurl.com/4ab7nhtp

Learning from a decade of progress in amyloidosis

Improving outcomes for people with rare diseases is a major challenge, but it is possible. Amyloidosis is a heterogeneous group of rare disorders in which amyloid (misfolded protein deposits) accumula...

tinyurl.com